Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

NCT04538352 · Completed

Last updated 2026-05-28

This clinical trial tests whether switching adults with type 2 diabetes from daily insulin injections to a once-weekly injection of semaglutide combined with basal insulin can safely lower blood sugar levels.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 60 people

Who can join Ages 18–75 · all sexes

Timeline Started 2021-01 · est. completion 2023-11

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04538352 ↗

Description as written by the study sponsor.

This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple daily injections of insulin (MDI), in patients with T2D with adequate glycemic control (≤ 7.5%) on MDI-based regimens (≤ 80 units of insulin per day), vs. further titration of insulin therapy in those continuing MDI. Weight loss, hypoglycemic episodes, and improvement in diabetes-treatment satisfaction will also be assessed between the two groups.

Treatments tested

Semaglutide also known as Ozempic Drug

Medication for type 2 diabetes management
Insulin Degludec also known as Tresiba Drug

Medication for type 2 diabetes management
Insulin aspart also known as Novolog Drug

Medication for type 2 diabetes management (rapid-acting)

Main thing measured	Mean Change in HbA1C ≤ 7.5%
Sponsor	The Cleveland Clinic
Conditions studied	Type 2 Diabetes
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04538352 ↗